---
title: "Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Limitations of current therapies"
description: "Formulary evidence on Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Limitations of current therapies. Topics: Summary: limitations of complement inhibitor therapy; No visual function benefit in the pivotal trials; Guideline position on monitoring, long-term data, and shared decision-making; Pooled effects of complement inhibitors on visual acuity, lesion growth, and adverse events; 8 further topics. 12 evidence topics quoted from 14 sources."
canonical: "https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description/limitations-of-current-therapies"
published: "2026-11-15T20:23:59-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Limitations of current therapies

<a id="heading-2.2.2.1.6"></a>

## 2.2.2.1.6 Limitations of Current Therapies

<a id="topic-2.2.2.1.6-1"></a>

### Summary: limitations of complement inhibitor therapy

Two intravitreal complement inhibitors are approved by the FDA for geographic atrophy: pegcetacoplan (C3 inhibitor), given every 25 to 60 days, and avacincaptad pegol (C5 inhibitor), given once monthly (approximately every 28 ± 7 days). Both reduced the growth of geographic atrophy lesions in sham-controlled phase 3 trials (pegcetacoplan by 22% monthly and 18% every other month at 24 months in OAKS; avacincaptad pegol by 14% in square-root-transformed growth at 12 months and by 14% at 24 months with monthly dosing in GATHER2). Neither improved visual function: the AAO Preferred Practice Pattern states that “There was no benefit for BCVA in the clinical trials for either pegcetacoplan or avacincaptad pegol”, and the 2023 Cochrane review of 10 randomized trials (4052 participants) found “no evidence that complement inhibition with any agent improves functional endpoints in advanced AMD”. The avacincaptad pegol finding of fewer eyes with persistent vision loss comes from a post hoc analysis of 12-month data.

Treatment requires indefinite intravitreal injections. In OAKS and DERBY, 21% to 31% of participants in the pegcetacoplan arms discontinued treatment before month 24. In a retrospective real-world cohort of eyes treated with pegcetacoplan or avacincaptad pegol, retention declined over the first 12 months, and pegcetacoplan treatment (hazard ratio 3.32), new neovascular AMD (odds ratio 3.02), and poor baseline visual acuity were associated with attrition.

Both products increase conversion to neovascular AMD: 12% with monthly and 7% with every-other-month pegcetacoplan against 3% with control by month 24, and 12% with avacincaptad pegol against 9% with sham over 24 months in GATHER2. Pegcetacoplan carries a warning for retinal vasculitis and/or retinal vascular occlusion, which may occur with the first dose and may cause severe vision loss. A postmarketing case series confirmed retinal vasculitis in 14 eyes of 13 patients, all after the first injection, with a more than 6-line loss of visual acuity in 6 eyes (43%); the guideline cites a postmarketing rate of 0.01% per injection. No retinal vasculitis was reported in the pivotal trials, which had no protocol for angiography in eyes with intraocular inflammation.

Neither product is authorized in the European Union. The European Medicines Agency confirmed its recommendation to refuse marketing authorisation for pegcetacoplan on 19 September 2024 because slowing lesion growth “did not lead to clinically meaningful benefits for patients”, and Astellas withdrew its application for avacincaptad pegol on 24 October 2024 after the Agency's provisional opinion that the product could not have been authorised. NICE suspended its appraisal of pegcetacoplan in February 2025, after the company reported that it did not receive marketing authorisation from the MHRA and has since discontinued it. The guideline notes that long-term, real-world data for both products are lacking.

Source: [Apellis Pharmaceuticals Syfovre prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/217171Orig1s003lbl.pdf); [Astellas Pharma US Izervay prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217225s004lbl.pdf); [Vemulakonda et al. (2025)](https://www.aao.org/Assets/f832e5ac-c047-4d1c-bdab-c5e52173623d/638760137410500000/age-related-macular-degeneration-ppp-pdf); [Heier et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37865470/); [Khanani et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37696275/); [Khanani et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41407269/); [Danzig et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38719191/); [Tzoumas et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10266126/); [Bhavsar et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42534291/); [Witkin et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10786078/); [European Medicines Agency Syfovre (2025)](https://www.ema.europa.eu/en/medicines/human/EPAR/syfovre); [European Medicines Agency Izelvay (2025)](https://www.ema.europa.eu/en/medicines/human/EPAR/izelvay); [National Institute for Health and Care Excellence pegcetacoplan appraisal (2026)](https://www.nice.org.uk/guidance/discontinued/gid-ta11351)

<a id="topic-2.2.2.1.6-2"></a>

### No visual function benefit in the pivotal trials

> “In both trials, there was no difference in either treatment arm versus sham for functional testing, including best corrected VA (BCVA), mesopic microperimetry, and reading speed.”
> “There was no difference in treatment group versus sham for functional tests of BCVA and low luminance BCVA.”
> “There was no benefit for BCVA in the clinical trials for either pegcetacoplan or avacincaptad pegol, although the post hoc analysis for avacincaptad pegol suggested a possible slowing of progression to persistent vision loss.”

Source: [Vemulakonda et al. (2025)](https://www.aao.org/Assets/f832e5ac-c047-4d1c-bdab-c5e52173623d/638760137410500000/age-related-macular-degeneration-ppp-pdf)

<a id="topic-2.2.2.1.6-3"></a>

### Guideline position on monitoring, long-term data, and shared decision-making

> “Because of the risk of exudative AMD, patients should be monitored and treated if needed.”
> “Pegcetacoplan and avacincaptad pegol are both relatively new medications for which long-term, real-world data are lacking.”
> “The physician should discuss the use of these medications with the patient, based on individual circumstances, including documented treatment benefits and risks.”

Source: [Vemulakonda et al. (2025)](https://www.aao.org/Assets/f832e5ac-c047-4d1c-bdab-c5e52173623d/638760137410500000/age-related-macular-degeneration-ppp-pdf)

<a id="topic-2.2.2.1.6-4"></a>

### Pooled effects of complement inhibitors on visual acuity, lesion growth, and adverse events

> “Ten RCTs with 4052 participants and eyes with GA were included.”
> “For 242 participants in one study, pegcetacoplan probably did not meaningfully change BCVA given monthly (+1.05 letters, 95% CI −2.71 to 4.81) or EOM (−1.42 letters, 95% CI −5.25 to 2.41), as supported by moderate‐certainty evidence.”
> “These reductions correspond to 19.2% and 14.8% versus sham, respectively.”
> “In a study of 260 participants with extrafoveal or juxtafoveal GA, monthly avacincaptad pegol probably did not result in a clinically meaningful change in BCVA at 2 mg (+1.39 letters, 95% CI −5.89 to 8.67) or 4 mg (−0.28 letters, 95% CI −8.74 to 8.18), based on moderate‐certainty evidence.”
> “However, there is currently no evidence that complement inhibition with any agent improves functional endpoints in advanced AMD; further results from the phase 3 studies of pegcetacoplan and avacincaptad pegol are eagerly awaited.”
> “Progression to MNV or exudative AMD is a possible emergent adverse event of complement inhibition, requiring careful consideration should these agents be used clinically.”
> “Intravitreal administration of complement inhibitors is probably associated with a small risk of endophthalmitis, which may be higher than that of other intravitreal therapies.”

Source: [Tzoumas et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10266126/)

<a id="topic-2.2.2.1.6-5"></a>

### Patient acceptability of injections conditional on functional benefit

> “Intravitreal complement inhibitors injections (IVCIs) slowed progression of geographic atrophy (GA) lesions in several registration phase 3 trials although without benefit for prespecified secondary functional vision outcomes.”
> “This cross-sectional study of 153 UK-based patients with GA, more than half found intravitreal injections for GA at least very acceptable, assuming treatment had vision functional benefits.”

Source: [Dinah et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12464851/)

<a id="topic-2.2.2.1.6-6"></a>

### Treatment discontinuation in OAKS and DERBY

> “In OAKS, 31% of patients in the monthly group, 21% of patients in the every other month and 25% of the patients assigned to sham discontinued treatment prior to Month 24.”
> “In DERBY, 29% of patients in the monthly group, 22% of patients in the every other month and 21% of the patients assigned to sham discontinued treatment prior to Month 24.”

Source: [Apellis Pharmaceuticals Syfovre prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/217171Orig1s003lbl.pdf)

<a id="topic-2.2.2.1.6-7"></a>

### Real-world attrition on complement inhibitor therapy

> “To identify characteristics of patients with geographic atrophy (GA) who received pegcetacoplan or avacincaptad pegol and discontinued treatment.”
> “Treatment retention declined between 0 and 12 months.”
> “Baseline predictors of attrition were age older than 90 years (HR, 1.26; 95% CI, 1.03-1.55; P = .028), pegcetacoplan treatment (HR, 3.32; 95% CI, 2.92-3.76; P < .001)”
> “Significant predictors included new nAMD (OR, 3.02; 95% CI, 2.35-3.89; P < .001) and a loss of more than 5 ETDRS letters (OR, 1.36; 95% CI, 1.17-1.58; P < .001).”
> “Poor baseline vision and development of new nAMD are associated with patient attrition, and the combination of nAMD and GA and treatment burden challenges patient retention.”

Source: [Bhavsar et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42534291/)

<a id="topic-2.2.2.1.6-8"></a>

### New-onset exudative AMD with pegcetacoplan in OAKS and DERBY

> “New-onset exudative age-related macular degeneration was reported in 24 (11%), 16 (8%), and four (2%) patients in OAKS, and in 27 (13%), 12 (6%), and nine (4%) patients in DERBY receiving pegcetacoplan monthly, pegcetacoplan every other month, and sham, respectively, at 24 months.”

Source: [Heier et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37865470/)

<a id="topic-2.2.2.1.6-9"></a>

### Retinal vasculitis and intraocular inflammation after pegcetacoplan

> “Postmarketing surveillance revealed retinal vasculitis occurred at a rate of 0.01% per injection and appears to occur more commonly following the first injection at a rate of 1/4000 first injections.”
> “Pegcetacoplan was found to have a 2.1% to 3.8% rate of intraocular inflammation (not counting endophthalmitis).”

Source: [Vemulakonda et al. (2025)](https://www.aao.org/Assets/f832e5ac-c047-4d1c-bdab-c5e52173623d/638760137410500000/age-related-macular-degeneration-ppp-pdf)

> “There were no reported cases of retinal vasculitis or occlusive retinal vasculopathy in the clinical trials.”
> “Notably, however, there was no defined protocol in these studies to obtain angiography in cases of intraocular inflammation.”
> “Voluntary reporting of adverse events is inherently subject to underreporting, and it is possible that some cases of retinal vasculitis have not been reported to the ReST Committee, the company, or the FDA.”

Source: [Witkin et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10786078/)

<a id="topic-2.2.2.1.6-10"></a>

### European Medicines Agency refusal of pegcetacoplan

> “After re-examining its initial opinion, the European Medicines Agency issued its final opinion on 19 September 2024 in which it confirmed its recommendation to refuse marketing authorisation for Syfovre.”
> “At the time of the initial evaluation, although the studies showed that Syfovre slowed the growth of geographic atrophy lesions, the Agency considered that this did not lead to clinically meaningful benefits for patients.”
> “It was noted that benefits of a treatment should have an impact on patients’ everyday functioning, and this was not demonstrated in the studies.”
> “In terms of safety, regular injections into the eye carry a significant risk of adverse events, including the development of other forms of AMD or inflammation in the eye, which could further worsen vision.”

Source: [European Medicines Agency Syfovre (2025)](https://www.ema.europa.eu/en/medicines/human/EPAR/syfovre)

<a id="topic-2.2.2.1.6-11"></a>

### Withdrawal of the European marketing authorisation application for avacincaptad pegol

> “Astellas Pharma Europe B.V. withdrew its application for a marketing authorisation of Izelvay, a medicine intended for the treatment of geographic atrophy caused by age-related macular degeneration (AMD).”
> “The company withdrew the application on 24 October 2024.”
> “Although the studies provided by the applicant showed that Izelvay slowed the growth of geographic atrophy lesions, the Agency considered that this effect did not lead to clinically meaningful improvements in visual function for patients.”
> “In its letter notifying the Agency of the withdrawal of the application, the company stated that it withdrew the application because of the Agency’s concerns about the effectiveness of the medicine.”

Source: [European Medicines Agency Izelvay (2025)](https://www.ema.europa.eu/en/medicines/human/EPAR/izelvay)

<a id="topic-2.2.2.1.6-12"></a>

### Discontinued NICE appraisal of pegcetacoplan

> “For information, the company have advised that they did not receive Marketing Authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) for this indication.”
> “Please note that following on from information provided to NICE by the company in February 2025, the appraisal was suspended from NICE’s work programme.”
> “As no further information has been received from the company the topic has been discontinued.”

Source: [National Institute for Health and Care Excellence pegcetacoplan appraisal (2026)](https://www.nice.org.uk/guidance/discontinued/gid-ta11351)

## Related pages
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Terms and abbreviations](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations.md)
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Product information and disease description](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Clinical evidence](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Economic information and modeling report](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: References](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references.md)
